Related Experiment Video

Updated: Jul 16, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Genetic explanation for cisplatin-induced ear damage

Kathryn Senior

    The Lancet. Oncology
    |March 14, 2007
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
    13:25

    Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

    Published on: May 15, 2021

    Related Experiment Videos

    Last Updated: Jul 16, 2026

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
    09:52

    Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

    Published on: March 16, 2018

    Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
    13:25

    Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

    Published on: May 15, 2021

    Related Concept Videos

    Nucleotide Excision Repair01:38

    Nucleotide Excision Repair

    DNA Distortion and Damage
    Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
    Nucleotide Excision Repair01:08

    Nucleotide Excision Repair

    Overview

    Articles linked to this work by shared authors, journal, and citation graph.

    Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet. Oncology·2026

    Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

    The Lancet. Oncology·2026

    Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

    The Lancet. Oncology·2026

    Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

    The Lancet. Oncology·2026

    A Novel 7 Sialylation-Related LncRNA Signature as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

    Current medicinal chemistry·2026

    Prediction of meningioma shrinkage after cyproterone acetate cessation.

    Neuro-oncology advances·2026

    Risk of colorectal cancer incidence and mortality after removals of polyps: a cohort study using the UK Biobank.

    Annals of gastroenterology·2026

    <i>In vivo</i> assessment of melanoma based on photoacoustic absorption and viscoelasticity imaging.

    Biomedical optics express·2026

    High-sensitivity Raman spectroscopy for prostate cancer detection and tissue extraction guidance.

    Biomedical optics express·2026

    Development and validation of a multimodal interpretable machine learning model for the identification of osteoporosis in patients with type 2 diabetes mellitus: a multicenter retrospective study.

    Frontiers in endocrinology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us